Patent 7666622 was granted and assigned to Regeneron Pharmaceuticals, Inc. on February, 2010 by the United States Patent and Trademark Office.
Monomeric fusion polypeptides comprising R1-M-L-M, wherein R1 is a target ligand-binding domain, M is a multimerizing component, and L is a linker capable of allowing one M component to interact with the other M component to form a self-associating monomer, optionally comprising a second target ligand-binding domain R2. Preferred target ligands include interleukin (IL)-13, IL-1, insulin-like growth factor (IGF)-1 and IGF-2.